Levetiracetam for partial seizures

Ovid Technologies (Wolters Kluwer Health) - Tập 55 Số 2 - Trang 236-242 - 2000
James J. Cereghino1,2,3,4, Victor Biton1,4, Bassel Abou‐Khalil1,4, Fritz E. Dreifuss1,4, Laura J. Gauer1,4, Ilo E. Leppik1,4
1From Oregon Health Sciences University (Dr. Cereghino)Portland; Arkansas Epilepsy Program (Dr. Biton), Little Rock; Vanderbilt Medical Center (Dr. Abou-Khalil), Nashville, TN; University of Virginia Hospital (Dr. Dreifuss
2University of Virginia Hospital (Dr. Dreifuss
3Vanderbilt Medical Center (Dr. Abou-Khalil), Nashville, TN
4†), Charlottesville; UCB Pharma (L.J. Gauer), Smyrna, GA; and the Minnesota Comprehensive Epilepsy Program (Dr. Leppik), Minneapolis.

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1016/0014-2999(92)90855-X

10.1016/0920-1211(95)00077-1

10.1016/S0014-2999(98)00410-5

10.1016/0014-2999(93)90768-D

Löscher W, Hönack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284:474–479.

10.1016/S0163-7258(99)00052-2

10.1016/S0920-1211(96)00031-9

Nicolas J-M, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999;27:250–254.

10.1111/j.1528-1157.1998.tb05128.x

US Food and Drug Administration.“COSTART” coding symbols for thesaurus of Adverse (sic) reaction terms. 5th ed. Rockville MD:DHHS 1995.

Cramer JA Arrigo C Van Hammee G et al. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 2000 (in press).

Thông tin
Thông tin xuất bản

Ovid Technologies (Wolters Kluwer Health)

Tập 55 Số 2

236-242

Thông tin tác giả